138772-65-3

Upstream product

• 3182-95-4 L-Phenylalaninol 
• 3674-06-4 Boc-Phe-ONSu 
• 67729-36-6 Boc-Phe-O-COO-isoBu 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 51987-73-6 (S)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 13122-89-9 (S)-methyl 2-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropanamido)-3-phenylpropanoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 63-91-2 L-phenylalanine 
• 13122-90-2 Boc-Phe-Phe-OH 

Downstream Products

• 94343-39-2 (S)-2-amino-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-3-phenylpropanamide 
• 383129-51-9 Boc-Phe-Phe-H 
• 80780-41-2 aurantiamide acetate 
• 153864-35-8 tert-butyl (S)-1-oxo-3-phenyl-1-((S)-1-phenylbut-3-en-2-ylamino)propan-2-ylcarbamateas 
• 1414493-15-4 tert-butyl (2S,5S,6S)-2,5-dibenzyl-6-(iodomethyl)-3-oxopiperazine-1-carboxylate 
• 138772-73-3 Acetic acid (S)-2-((S)-2-amino-3-phenyl-propionylamino)-3-phenyl-propyl ester; compound with trifluoro-acetic acid 

Relevant academic research and scientific papers

Aurantiamide acetate and fluorinated derivatives thereof as well as preparation method and application thereof

The invention belongs to the technical field of medicines, and discloses aurantiamide acetate and fluorinated derivatives thereof, and a preparation method and application thereof. The general formulaof the aurantiamide acetate, the aurantiamide acetate fluorinated derivatives or pharmaceutically acceptable salts of the aurantiamide acetate and the aurantiamide acetate fluorinated derivatives isshown in the specification, wherein R1 represents OH, CH2OH or OCOCH3, and R2, R3 and R4 each independently represent H, an alkyl group or F. The aurantiamide acetate and the fluorinated derivatives or the pharmaceutically acceptable salts thereof have a good effect of preventing or treating influenza viruses, especially infection caused by influenza A viruses. The aurantiamide acetate is subjected to fluorination modification, so that the biological activity of the aurantiamide acetate is stronger. The aurantiamide acetate and the fluorinated derivative thereof act on a target to aim at viruses and also aim at host cells, so that drug resistance is not easy to generate.

Organobase-catalyzed amidation of esters with amino alcohols

A base-mediated procedure for the amidation of unactivated esters with amino alcohols is reported. Optimization and exemplification of the catalytic process are described, furnishing products in 40-100% isolated yield.

An efficient entry to highly substituted chiral 2-oxopiperazines from α-amino acids via iodocyclization

A short and stereoselective route for the synthesis of 2-oxopiperazines is presented starting from different naturally abundant α-amino acids. The key synthetic steps involved amide coupling, Wittig reaction, HWE olefination, aza-Michael reaction, iodocyc

PHENYLALANINE DIPEPTIDE DERIVATIVES, COMPOSITIONS AND USE THEREOF

Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the smae, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat hepatitis B virus and human immunodeficiency virus with little toxic side effects.

Design and synthesis of new N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides as anti-inflammatory agents

Twenty-four new dipeptide analogs (1-24) of aurantiamide acetate were designed, synthesized, and assayed for effects on superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB. Among them, seven N-(fluorenyl-9-methoxycarbonyl) (Fmoc)-dipeptides (6, 9, 12, 14, 17, 18 and 20) showed potent inhibitory effects. Compounds 9 and 18 showed the most selective effects against human neutrophil elastase release, with IC50 values of 0.8 ± 0.1 and 1.7 ± 0.6 μM, respectively, and were 130-fold more potent than phenylmethylsulfonyl fluoride (PMSF), the positive control, in this anti-inflammatory assay. These two compounds could be developed as new lead anti-inflammatory agents.

Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling

Endomorphin-2 (EM-2) is a putative endogenous μ-opioid receptor ligand. To get insight into the important role of C-terminal amide group of EM-2, we investigated herein a series of EM-2 analogs by substitution of the C-terminal amide group with -NHNH2, -NHCH3, -N(CH3)2, -OCH3, -OCH2CH3, -OC(CH3)3, and -CH2-OH. Their binding affinity and bioactivity were determined and compared. Despite similar (analogs 1, 4, and 7) or decreased (analogs 2, 3,5, and 6) μ affinity in binding assays, all analogs showed low guinea pig ileum (GPI) and mouse vas deferens (MVD) potencies compared to their parent peptide. Interestingly, as for analogs 2 and 3 (a single and double N-methylation of C-terminal amide), the potency order with the Ki (μ) values was 2 > 3; for the C-terminal esterified analogs 4-6, the potency order with the Ki (μ) values was 4 > 5 > 6. Thus, we concluded that the steric hindrance of C-terminus might play an important role in opioid receptor affinity. We further investigated the conformational properties of these analogs by 1D and 2D 1H NMR spectroscopy and molecular modeling. Evaluating the ratios of cis- and trans-isomers, aromatic interactions, dihedral angles, and stereoscopic views of the most convergent conformers, we found that modifications at the C-terminal amide group of EM-2 affected these analog conformations markedly, therefore changed the opioid receptor affinity and in vitro bioactivity.

A facile and simple method for the reduction of N-protected amino acids and peptides to the corresponding alcohols

A practical and chemoselective method for the reduction of N-protected amino acids and peptides including carboxylic acids to their corresponding alcohols is outlined.

Employing the structural diversity of nature: Development of modular dipeptide-analogue ligands for ruthenium-catalyzed enantioselective transfer hydrogenation of ketones

A library of novel dipeptideanalogue ligands based on the combination of tert-butoxycarbonyl(N-Boc)-protected a-amino acids and chiral vicinal amino alcohols were prepared. These highly modular ligands were combined with [{RuCl2(p-cymene)}2 and the resulting metal complexes were screened as catalysts for the enantioselective reduction of acetophenone under transfer hydrogenation conditions using 2-propanol as the hydrogen donor. Excellent enantioselectivity of 1-phenylethanol (up to 98% ee) was achieved with several of the novel catalysts. Although most of the ligands contained two stereocenters, it was demonstrated that the absolute configuration of the product alcohol was determined by the configuration of the amino acid part of the ligand. Employing ligands based on L-amino acids generated S-configured products, and catalysts based on Damino acids favored the formation of the R-configured alcohol. The combination N-Boc-L-alanine and (R)-phenylglycinol (Boc-L-Ab) or its enantiomer (N-Boc-D-alanine and (S)-phenylglycinol, Boc-D-Aa) proved to be the best ligands for the reduction process. Transfer hydrogenation of a number of aryl alkyl ketones were evaluated and excellent enantioselectivity, up to 96 % ee, was obtained.

A DIPEPTIDE DERIVATIVE FROM HYPERICUM JAPONICUM

The structure of a novel peptide analogue saropeptate, N-benzoyl-L-phenylalanyl-L-phenylalaninol acetate, isolated from the whole plant of H. japonicum was elucidated by spectroscopic analysis and its absolute configuration determined by comparison with four synthetic diastereoisomers.Key Word Index - Hypericum japonicum; Guttiferae; dipeptide derivative; N-benzoyl-L-phenylalanyl-L-phenylalaninol acetate.